IMM60 and Pembrolizumab in Melanoma and NSCLC

Clinical trial NCT05709821 · TERMINATED

Trial details

NCT number: NCT05709821
Sponsor: iOx Therapeutics
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer Melanoma

Start date: 2023-11-15
Primary completion: 2024-04-22
Enrollment: 1

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.